
ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval
11.11.2026
0:00
1:41
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
Więcej odcinków z kanału "Applied Clinical Trials"



Nie przegap odcinka z kanału “Applied Clinical Trials”! Subskrybuj bezpłatnie w aplikacji GetPodcast.








